METHODS FOR MAKING COMPOSITIONS COMPRISING HEAT SHOCK PROTEINS OR ALPHA-2-MACROGLOBULIN FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASE
    2.
    发明申请
    METHODS FOR MAKING COMPOSITIONS COMPRISING HEAT SHOCK PROTEINS OR ALPHA-2-MACROGLOBULIN FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASE 审中-公开
    包含热休克蛋白或ALPHA-2-MACROGLOBULIN用于治疗癌症和感染性疾病的组合物的方法

    公开(公告)号:WO2005120558A3

    公开(公告)日:2007-03-29

    申请号:PCT/US2005018471

    申请日:2005-05-25

    CPC分类号: A61K39/0011 A61K2039/6043

    摘要: The present invention relates to methods for making complexes of HSP or alpha-2 macroglobulin and antigenic peptides, and uses of such complexes for the prevention and treatment of infectious diseases, cancers, and metabolic disorders. The methods of the invention comprises treating a purified target antigen preparation with a protease and/or a chemical to generate an antigenic set of peptides which is complexed to HSP or alpha-2 macroglobulin. Also encompassed in the invention are compositions comprising complexes of HSP or alpha-2 macroglobulin and antigenic peptides.

    摘要翻译: 本发明涉及制备HSP或α-2巨球蛋白和抗原肽复合物的方法,以及这些复合物用于预防和治疗感染性疾病,癌症和代谢紊乱的方法。 本发明的方法包括用蛋白酶和/或化学药剂处理纯化的靶抗原制剂以产生与HSP或α-2巨球蛋白复合的抗原性肽组。 还包括在本发明中的是包含HSP或α-2巨球蛋白和抗原肽的复合物的组合物。

    IMMUNOTHERAPY OF CANCER THROUGH CONTROLLED CELL LYSIS
    3.
    发明申请
    IMMUNOTHERAPY OF CANCER THROUGH CONTROLLED CELL LYSIS 审中-公开
    通过控制细胞淋巴瘤对癌症进行免疫治疗

    公开(公告)号:WO2004037321A3

    公开(公告)日:2005-10-06

    申请号:PCT/US0334283

    申请日:2003-10-27

    摘要: The treatment device includes an extraction mechanism, configured to extract a tissue sample from a patient or a tumor, coupled to a lysis mechanism. The lysis mechanism is configured to induce lysis of the tissue sample into a lysed tissue sample. The treatment device also includes an administration mechanism that is coupled to both the extraction mechanism and the lysis mechanism. Further included with the treatment device is an additive mechanism configured to add an additive solution to the lysed tissue sample before the lysed tissue sample is administered to the patient. Furthermore, the invention also provided a method for treating a cancer. The method includes the steps of extracting a tissue sample from a patient or a tumor into a chamber of a treatment device. Lysing the tissue sample into an laysed tissue sample within the chamber of the treatment device and administering the lysed tissue sample directly from the treatment device into the patient.

    摘要翻译: 治疗装置包括提取机构,其配置为从患者或肿瘤提取组织样品,其与裂解机制偶联。 裂解机制被配置为诱导组织样品裂解成裂解的组织样品。 处理装置还包括与提取机构和裂解机构相结合的施用机构。 治疗装置还包括一种添加机制,其被配置为在将裂解的组织样品施用于患者之前将添加剂溶液添加到裂解的组织样品。 此外,本发明还提供了治疗癌症的方法。 该方法包括将组织样本从患者或肿瘤提取到治疗装置的腔室中的步骤。 将组织样品裂解成处理装置的腔室内的铺设的组织样品,并将裂解的组织样品直接从治疗装置进入患者体内。

    IMMUNOGENIC ACUTE PHASE PROTEIN-ANTIGENIC MOLECULE COMPLEXES AND FUSION PROTEINS
    4.
    发明申请
    IMMUNOGENIC ACUTE PHASE PROTEIN-ANTIGENIC MOLECULE COMPLEXES AND FUSION PROTEINS 审中-公开
    免疫原性相对蛋白 - 抗原分子复合物和融合蛋白

    公开(公告)号:WO2004069208A3

    公开(公告)日:2005-01-27

    申请号:PCT/US2004003866

    申请日:2004-02-04

    摘要: The present invention relates to complexes and fusion proteins comprising an acute phase protein and an antigenic molecule, for use in the treatment or prevention of a disease. The invention specifically provides for complexes comprising an acute phase protein noncovalently bound to, or alternatively crosslinked to, an antigenic molecule. The invention also specifically provides fusion proteins comprising an acute phase protein fused via a peptide bond to an antigenic molecule.

    摘要翻译: 本发明涉及包含急性期蛋白质和抗原性分子的复合物和融合蛋白,用于治疗或预防疾病。 本发明特别提供了包含非共价结合或交联至抗原分子的急性期蛋白质的复合物。 本发明还具体提供了融合蛋白,其包含通过肽键与抗原分子融合的急性期蛋白。

    IMMUNOGENIC CD19 LIGAND-ANTIGENIC MOLECULE COMPLEXES AND FUSION PROTEINS
    6.
    发明申请
    IMMUNOGENIC CD19 LIGAND-ANTIGENIC MOLECULE COMPLEXES AND FUSION PROTEINS 审中-公开
    免疫原CD19配体 - 抗原分子复合物和融合蛋白

    公开(公告)号:WO2004080387A3

    公开(公告)日:2009-03-26

    申请号:PCT/US2004003642

    申请日:2004-02-04

    摘要: The present invention relates to complexes and fusion proteins comprising a CD91 ligand and an antigenic molecule, for use in the treatment or prevention of a disease. The invention specifically provides complexes comprising a CD91 ligand noncovalently boundto, or alternatively crosslinked to, an antigenic molecule. The invention also specifically provides fusion proteins comprising a CD91 ligand fused via a peptide bond to an antigenic molecule.

    摘要翻译: 本发明涉及包含CD91配体和抗原性分子的复合物和融合蛋白,用于治疗或预防疾病。 本发明特别提供了包含非共价结合到或者交联到抗原分子的CD91配体的复合物。 本发明还具体提供了包含通过肽键与抗原分子融合的CD91配体的融合蛋白。

    IMMUNOGENIC CD91 LIGAND-ANTIGENIC MOLECULE COMPLEXES AND FUSION PROTEINS
    7.
    发明申请
    IMMUNOGENIC CD91 LIGAND-ANTIGENIC MOLECULE COMPLEXES AND FUSION PROTEINS 审中-公开
    免疫原CD91配体 - 抗原分子复合物和融合蛋白

    公开(公告)号:WO2004069206A3

    公开(公告)日:2008-01-24

    申请号:PCT/US2004003864

    申请日:2004-02-04

    摘要: The present invention relates to complexes and fusion proteins comprising a CD91 ligand and an antigenic molecule, for use in the treatment or prevention of a disease. The invention specifically provides complexes comprising a CD91 ligand noncovalently bound to, or alternatively crosslinked to, an antigenic molecule. The invention also specifically provides fusion proteins comprising a CD91 ligand fused via a peptide bond to an antigenic molecule.

    摘要翻译: 本发明涉及包含CD91配体和抗原性分子的复合物和融合蛋白,用于治疗或预防疾病。 本发明特别提供了包含非共价结合或交联至抗原分子的CD91配体的复合物。 本发明还具体提供了包含通过肽键与抗原分子融合的CD91配体的融合蛋白。

    HEAT SHOCK PROTEIN BINDING FRAGMENTS OF CD91, AND USES THEREOF
    9.
    发明申请
    HEAT SHOCK PROTEIN BINDING FRAGMENTS OF CD91, AND USES THEREOF 审中-公开
    CD91的热休克蛋白质结合片段及其用途

    公开(公告)号:WO2004033657A3

    公开(公告)日:2006-08-31

    申请号:PCT/US0332167

    申请日:2003-10-07

    摘要: The present invention relates to compositions and methods for the use of natural and recombinant p95 forms and fragments as heat shock protein binding proteins. The invention is based, in part, on the Applicant's discovery that a p95 can be recombinantly expressed. The present invention also relates to CD91 polypeptide fragments that comprise at least p95 and additional contiguous sequence from domain II, III, and IV of CD91. The present invention provides nucleic acid molecules encoding a CD91 polypeptide fragment or an analog, derivative or mimetic thereof, CD91 polypeptide fragments, or analogs, derivatives or mimetics thereof, vectors comprising a nucleic acid molecule encoding a CD91 polypeptide fragment, expression vectors comprising a nucleic acid molecule encoding a CD91 polypeptide fragment, eukaryotic and prokaryotic cells recombinantly expressing a CD91 polypeptide fragment, methods of identifying compounds that interact with a CD91 polypeptide fragment or the interaction of a CD91 polypeptide fragment and CD91 ligands, methods for modulating an immune response with the compositions and methods of the invention, and methods for treatment using the compositions and methods disclosed herein.

    摘要翻译: 本发明涉及使用天然和重组p95形式和片段作为热休克蛋白结合蛋白的组合物和方法。 本发明部分地基于申请人发现p95可重组表达。 本发明还涉及包含至少p95的CD91多肽片段和来自CD91的结构域II,III和IV的另外的连续序列。 本发明提供编码CD91多肽片段或其类似物,衍生物或模拟物,CD91多肽片段或其类似物,衍生物或模拟物的核酸分子,包含编码CD91多肽片段的核酸分子的载体,包含核酸的表达载体 编码CD91多肽片段的酸分子,重组表达CD91多肽片段的真核和原核细胞,鉴定与CD91多肽片段相互作用的化合物或CD91多肽片段和CD91配体的相互作用的方法,用于调节免疫应答的方法 本发明的组合物和方法,以及使用本文公开的组合物和方法进行治疗的方法。

    IMMUNOGENIC ACUTE PHASE PROTEIN-ANTIGENIC MOLECULE COMPLEXES AND FUSION PROTEINS
    10.
    发明申请
    IMMUNOGENIC ACUTE PHASE PROTEIN-ANTIGENIC MOLECULE COMPLEXES AND FUSION PROTEINS 审中-公开
    免疫原性急性期蛋白 - 抗原分子复合物和融合蛋白

    公开(公告)号:WO2004069204A3

    公开(公告)日:2004-11-25

    申请号:PCT/US2004003861

    申请日:2004-02-04

    摘要: The present invention relates to complexes and fusion proteins comprising an acute phase protein and an antigenic molecule, for use in the treatment or prevention of a disease. The invention specifically provides for complexes comprising an acute phase protein noncovalently bound to, or alternatively crosslinked to, an antigenic molecule. The invention also specifically provides fusion proteins comprising an acute phase protein fused via a peptide bond to an antigenic molecule.

    摘要翻译: 本发明涉及包含急性期蛋白质和抗原性分子的复合物和融合蛋白,用于治疗或预防疾病。 本发明特别提供了包含与抗原性分子非共价结合或交替结合的急性期蛋白质的复合物。 本发明还具体提供了包含通过肽键与抗原性分子融合的急性期蛋白质的融合蛋白。